The FDA approved the monobactam/beta-lactamase inhibitor combination for use in combination with metronidazole to treat patients who have limited or no treatment options for cIAIs caused by gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex, and Serratia marcescens.
